Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference
HOUSTON , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the
View HTML
Toggle Summary Aravive Announces Pricing of Public Offering of Common Stock
HOUSTON , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) , (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced the pricing of its previously
View HTML
Toggle Summary Aravive Announces Proposed Public Offering of Common Stock
HOUSTON , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) , (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that it has commenced an underwritten
View HTML
Toggle Summary Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer
Statistically significant four-fold increase in progression free survival observed in women with high AVB-500 levels Progression Free Survival of AVB-500 over time in Days Aravive to Host Conference Call Today at 8 a.m. EST HOUSTON, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc.
View HTML
Toggle Summary Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of
View HTML
Toggle Summary CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
HOUSTON , Nov. 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, November 7th by  Aravive, Inc. (Nasdaq: ARAV), please note that in the last sentence of the second paragraph, the year for the IgA Nephropathy study should be 2019, not 2020.
View HTML
Toggle Summary Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
HOUSTON , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the
View HTML
Toggle Summary Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research
AVB-500 reduced tumor size and blood vessel density in animal models Study highlights role of GAS6/AXL signaling in promoting tumor angiogenesis through regulation of plasminogen receptor S100A10 Data supports Aravive’s clinical development plan in clear cell renal cell carcinoma (ccRCC) HOUSTON ,
View HTML
Toggle Summary Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
Company additionally reports data on initial 28 evaluable patients in ongoing expansion study as well as expansion cohort dose increase based on drug exposure-response analysis   HOUSTON , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial
View HTML
Toggle Summary Aravive Announces Participation at the 2019 Cantor Global Healthcare Conference
HOUSTON , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the
View HTML